Jianya Gao , Xiaochun Liu , Jieyao Huang , Xiaofei Bi , Yanjun Hu , Tian Chen , Qiuyan Sun , Wei Fang , Yaping Xiao
{"title":"橘皮素通过下调MAOA抑制炎症反应,保护肾脏免受缺血再灌注损伤","authors":"Jianya Gao , Xiaochun Liu , Jieyao Huang , Xiaofei Bi , Yanjun Hu , Tian Chen , Qiuyan Sun , Wei Fang , Yaping Xiao","doi":"10.1016/j.intimp.2025.115242","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>This study investigates the protective effects and mechanisms of the natural antioxidant tangeretin in alleviating renal ischemia-reperfusion injury (RIRI), a major cause of acute kidney injury (AKI).</div></div><div><h3>Methods</h3><div>Firstly, a RIRI mouse model was established to investigate the renoprotective effects of tangeretin. Potential therapeutic targets were identified through RNA sequencing and network pharmacology analysis and subsequently validated using the GEO and KIT databases. Next, the interactions between key targets and ligands were examined using molecular docking and molecular dynamics simulations. Finally, RT-qPCR, immunohistochemistry, Western blotting, and pharmacological inhibition assays were used to verify the expression profiles and functional roles of these targets as well as their involvement in relevant signaling pathways.</div></div><div><h3>Results</h3><div>Tangeretin significantly improved renal function and attenuated histopathological damage in mice subjected to RIRI. Monoamine oxidase A (MAOA) was identified as a potential therapeutic target and was found to be markedly upregulated in RIRI, as confirmed by public database analyses. Molecular docking and molecular dynamics simulations revealed the stable binding interaction between tangeretin and MAOA. Experimental validation demonstrated that tangeretin inhibited MAOA/NF-κB signaling and effectively reduced renal cell apoptosis. Moreover, the protective effects of tangeretin on renal function, inflammation, and MAOA regulation were similar to those of the MAOA inhibitor tranylcypromine.</div></div><div><h3>Conclusion</h3><div>Tangeretin attenuates RIRI-induced renal injury by inhibiting the MAOA/NF-κB pathway and exerting anti-inflammatory and anti-apoptotic effects. These findings highlight its potential as a promising therapeutic candidate for ischemia-associated AKI.</div></div>","PeriodicalId":13859,"journal":{"name":"International immunopharmacology","volume":"163 ","pages":"Article 115242"},"PeriodicalIF":4.7000,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Tangeretin protects the kidney from ischemia-reperfusion injury by inhibiting inflammatory response through downregulation of MAOA\",\"authors\":\"Jianya Gao , Xiaochun Liu , Jieyao Huang , Xiaofei Bi , Yanjun Hu , Tian Chen , Qiuyan Sun , Wei Fang , Yaping Xiao\",\"doi\":\"10.1016/j.intimp.2025.115242\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objective</h3><div>This study investigates the protective effects and mechanisms of the natural antioxidant tangeretin in alleviating renal ischemia-reperfusion injury (RIRI), a major cause of acute kidney injury (AKI).</div></div><div><h3>Methods</h3><div>Firstly, a RIRI mouse model was established to investigate the renoprotective effects of tangeretin. Potential therapeutic targets were identified through RNA sequencing and network pharmacology analysis and subsequently validated using the GEO and KIT databases. Next, the interactions between key targets and ligands were examined using molecular docking and molecular dynamics simulations. Finally, RT-qPCR, immunohistochemistry, Western blotting, and pharmacological inhibition assays were used to verify the expression profiles and functional roles of these targets as well as their involvement in relevant signaling pathways.</div></div><div><h3>Results</h3><div>Tangeretin significantly improved renal function and attenuated histopathological damage in mice subjected to RIRI. Monoamine oxidase A (MAOA) was identified as a potential therapeutic target and was found to be markedly upregulated in RIRI, as confirmed by public database analyses. Molecular docking and molecular dynamics simulations revealed the stable binding interaction between tangeretin and MAOA. Experimental validation demonstrated that tangeretin inhibited MAOA/NF-κB signaling and effectively reduced renal cell apoptosis. Moreover, the protective effects of tangeretin on renal function, inflammation, and MAOA regulation were similar to those of the MAOA inhibitor tranylcypromine.</div></div><div><h3>Conclusion</h3><div>Tangeretin attenuates RIRI-induced renal injury by inhibiting the MAOA/NF-κB pathway and exerting anti-inflammatory and anti-apoptotic effects. These findings highlight its potential as a promising therapeutic candidate for ischemia-associated AKI.</div></div>\",\"PeriodicalId\":13859,\"journal\":{\"name\":\"International immunopharmacology\",\"volume\":\"163 \",\"pages\":\"Article 115242\"},\"PeriodicalIF\":4.7000,\"publicationDate\":\"2025-07-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International immunopharmacology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1567576925012329\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International immunopharmacology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1567576925012329","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
Tangeretin protects the kidney from ischemia-reperfusion injury by inhibiting inflammatory response through downregulation of MAOA
Objective
This study investigates the protective effects and mechanisms of the natural antioxidant tangeretin in alleviating renal ischemia-reperfusion injury (RIRI), a major cause of acute kidney injury (AKI).
Methods
Firstly, a RIRI mouse model was established to investigate the renoprotective effects of tangeretin. Potential therapeutic targets were identified through RNA sequencing and network pharmacology analysis and subsequently validated using the GEO and KIT databases. Next, the interactions between key targets and ligands were examined using molecular docking and molecular dynamics simulations. Finally, RT-qPCR, immunohistochemistry, Western blotting, and pharmacological inhibition assays were used to verify the expression profiles and functional roles of these targets as well as their involvement in relevant signaling pathways.
Results
Tangeretin significantly improved renal function and attenuated histopathological damage in mice subjected to RIRI. Monoamine oxidase A (MAOA) was identified as a potential therapeutic target and was found to be markedly upregulated in RIRI, as confirmed by public database analyses. Molecular docking and molecular dynamics simulations revealed the stable binding interaction between tangeretin and MAOA. Experimental validation demonstrated that tangeretin inhibited MAOA/NF-κB signaling and effectively reduced renal cell apoptosis. Moreover, the protective effects of tangeretin on renal function, inflammation, and MAOA regulation were similar to those of the MAOA inhibitor tranylcypromine.
Conclusion
Tangeretin attenuates RIRI-induced renal injury by inhibiting the MAOA/NF-κB pathway and exerting anti-inflammatory and anti-apoptotic effects. These findings highlight its potential as a promising therapeutic candidate for ischemia-associated AKI.
期刊介绍:
International Immunopharmacology is the primary vehicle for the publication of original research papers pertinent to the overlapping areas of immunology, pharmacology, cytokine biology, immunotherapy, immunopathology and immunotoxicology. Review articles that encompass these subjects are also welcome.
The subject material appropriate for submission includes:
• Clinical studies employing immunotherapy of any type including the use of: bacterial and chemical agents; thymic hormones, interferon, lymphokines, etc., in transplantation and diseases such as cancer, immunodeficiency, chronic infection and allergic, inflammatory or autoimmune disorders.
• Studies on the mechanisms of action of these agents for specific parameters of immune competence as well as the overall clinical state.
• Pre-clinical animal studies and in vitro studies on mechanisms of action with immunopotentiators, immunomodulators, immunoadjuvants and other pharmacological agents active on cells participating in immune or allergic responses.
• Pharmacological compounds, microbial products and toxicological agents that affect the lymphoid system, and their mechanisms of action.
• Agents that activate genes or modify transcription and translation within the immune response.
• Substances activated, generated, or released through immunologic or related pathways that are pharmacologically active.
• Production, function and regulation of cytokines and their receptors.
• Classical pharmacological studies on the effects of chemokines and bioactive factors released during immunological reactions.